Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Schroders Capital GIT joins Neurona Therapeutics funding round

(Sharecast News) - Schroders Capital Global Innovation Trust announced an investment of $1.6m (£1.3m) in Neurona Therapeutics, a prominent US-based clinical-stage cell therapy company, on Friday. The investment by the trust was part of Neurona's series E financing round, which successfully raised $120m.

Schroders said the financing round was co-led by Viking Global Investors and Cormorant Asset Management, and saw participation from a range of investors, both new and existing.

Neurona Therapeutics specialises in the development of allogeneic neural cell therapies aimed at addressing chronic diseases of the nervous system.

The funds procured from the financing round were earmarked to further the advancement of Neurona's pipeline of wholly-owned, off-the-shelf cell therapies across various indications.

Schroders said the lead investigational candidate, NRTX-1001, was currently under evaluation in an ongoing open-label, single-arm phase one and two clinical trial for the treatment of drug-resistant mesial temporal lobe epilepsy (MTLE).

Additionally, there was potential for its application in Alzheimer's disease treatment.

In December, Neurona reported positive outcomes from its clinical trials, indicating that NRTX-1001 had been well-tolerated among initial subjects.

The first two subjects continued to experience a significant reduction of over 95% in overall average monthly seizure counts one year after treatment.

Beyond NRTX-1001, Neurona was actively engaged in the preclinical development of three additional cell therapies.

"We are delighted to make another investment as part of the portfolio sub-strategy of backing innovative life science companies at the near-clinical or clinical stage of development," said lead portfolio manager Tim Creed and co-portfolio manager Harry Raikes in a joint statement.

"We believe Neurona is a highly complementary addition to the company's portfolio.

"This funding will help advance Neurona's cell therapies to address unmet needs in chronic neurological disorders and we are encouraged by the strength of the initial clinical data."

At 1233 GMT, shares in Schroders Capital Global Innovation Trust were down 0.11% in London at 12.34p.

Reporting by Josh White for

Share this article

Related Sharecast Articles

Easyjet suspends flights to Israel until October
(Sharecast News) - Budget carrier easyJet on Tuesday said it had suspended flights to Tel Aviv until October 27 after Iran's missile and drone attack against Israel on Saturday night.
Berenberg stays at 'buy' on Yellow Cake on tight supplies and supply risk
(Sharecast News) - Analysts at Berenberg stood by their 'buy' recommendation for shares of Yellow Cake, the uranium oxide concentrate holding company, following a fireside chat with its boss, Andre Liebenberg.
Bank of America upbeat despite profits slide
(Sharecast News) - Bank of America said it had seen a "strong" first quarter on Tuesday, despite posting a sharp fall in profits.
Berenberg lowers target price on Kainos
(Sharecast News) - Analysts at Berenberg lowered their target price on software company Kainos from 1,315.0p to 1,260.0p on Tuesday following the group's full-year trading update on 15 April.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.